PRLD (Prelude Therapeutics) Research & Development: $79.09 Mil (TTM As of Mar. 2026)


PRLD Prelude Therapeutics Inc PRLD
26 GF Score
Price $4.99
! 6 Warning Signs
View Full Analysis

What is Prelude Therapeutics Research & Development?

Prelude Therapeutics PRLD +1.63% 26 Research & Development is $79.09 Mil as of Mar. 2026. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Prelude Therapeutics's Research & Development for the three months ended in Mar. 2026 was $13.60 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $79.09 Mil.

Prelude Therapeutics  (NAS:PRLD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Prelude Therapeutics Research & Development Related Terms

Prelude Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Prelude Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prelude Therapeutics Research & Development Chart

Prelude Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 86.78 92.89 103.39 118.00 94.30

Prelude Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.82 25.78 21.71 17.99 13.60
PRLD
26GF Score
Prelude Therapeutics Inc PRLD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prelude Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $79.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $79.09 Mil mean?
Prelude Therapeutics (PRLD) has a Research & Development of $79.09 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Prelude Therapeutics and its competitors.
Is Prelude Therapeutics' Research & Development too high?
Prelude Therapeutics' current Research & Development is $79.09 Mil. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Research & Development compare to DMAC and RCKT?
Prelude Therapeutics' Research & Development of $79.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Prelude Therapeutics and its competitors. Prelude Therapeutics's current Research & Development is $79.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Research & Development of $79.09 Mil. The current Research & Development is $79.09 Mil. Prelude Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Research & Development is $79.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score

Get the complete analysis for PRLD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.99
Price